New Stock News: Handsuma Aitai plans to launch its IPO in Hong Kong. The China Securities Regulatory Commission requires additional clarification on whether the company's business is subject to restrictions or prohibitions in the negative list for access to foreign capital.

On January 17, the China Securities Regulatory Commission (CSRC) released the requirements for supplementary materials for overseas issuance and listing (January 10, 2025 - January 16, 2025) for public disclosure. The disclosure mentioned that Hansa Aetis should provide additional information on whether the company's business involves restrictions or prohibitions on foreign investment negative lists, and whether the issuance and listing, as well as the "full circulation" after that, continue to comply with foreign investment access requirements. According to the disclosure on November 24, 2024 by the Hong Kong Stock Exchange, Hansa Aetis submitted an application for listing on the main board of the Hong Kong Stock Exchange, with ICBC International as its exclusive sponsor. Specifically, the CSRC disclosure stated that Hansa Aetis should provide supplementary explanations on the following matters and have lawyers verify and provide clear legal opinions: 1. Please provide a detailed explanation based on the products and business operations of your company whether the business involves restrictions or prohibitions on the foreign investment negative list, and whether it continues to comply with foreign investment access requirements after the issuance and listing. 2. Please explain whether the original shareholder of Hangzhou Hansa Biopharmaceutical Co., Ltd. (Hangzhou Hansa) who obtained shares in your company during the restructuring has paid the capital contribution to Hangzhou Hansa. 3. Please explain whether there are any shares held by shareholders participating in the "full circulation" that are pledged, frozen, or subject to any disputes. According to the prospectus, Hansa Aetis is an innovative biotechnology company with proprietary technology and experience in structural biology, translational medicine, and clinical development. It is committed to developing next-generation immunotherapies, discovering, developing, and commercializing novel and/or best-in-class products for precise treatment of cancer and autoimmune diseases, addressing unmet medical needs globally.